Floatz logo

5-azacytidine

DLBCL - Diffuse Large B Cell Lymphoma

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

270 Active assets in the DLBCL - Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

5-azacytidine is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →